Abstract Alzheimer's disease (AD), the most common form of dementia worldwide, is a mixed
proteinopathy (β-amyloid, tau and other proteins). Classically defined as a …

The amyloid cascade hypothesis for Alzheimer's disease is still alive, although heavily
challenged. Effective anti-amyloid immunotherapy would confirm the hypothesis' claim that …

Alzheimer's disease (AD) is a progressive, neurodegenerative disorder that affects memory,
thinking, behavior, and other cognitive functions. Although there is no cure, detecting AD …

Abstract Introduction The Centiloid scale was developed to harmonise the quantification of β-
amyloid (Aβ) PET images across tracers, scanners, and processing pipelines. However …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve
Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging …

Amyloid-beta (Aβ) aggregates and myelin breakdown are among the earliest detrimental
effects of Alzheimer's disease (AD), likely inducing abnormal patterns of neuronal …

Passive immunotherapy for Alzheimer disease has been tried for over 10 years without
success. However, in 2021 and most recently in January 2023, the US Food and Drug …

PET imaging with β-amyloid ligands is emerging as a molecular imaging technique targeting
white matter integrity and demyelination. β-amyloid PET ligands such as 11C-Pittsburgh …

Background Accumulation of amyloid beta, tau hyperphosphorylation, and microglia
activation are the three highly acknowledged pathological factors of Alzheimer's disease …

Purpose The main objectives were to test whether (1) a decrease in myelin is associated
with enhanced rate of fibrillar tau accumulation and cognitive decline in Alzheimer's disease …